Management of Losartan and HCTZ in Patients with Moderate Kidney Impairment

Introduction to Losartan and HCTZ Management

The American College of Cardiology recommends that losartan can be safely continued without dose adjustment at eGFR 44 mL/min, but HCTZ should be replaced with a loop diuretic or discontinued, as thiazides lose efficacy and increase adverse effects when GFR falls below 45 mL/min 1, 2

The American College of Cardiology suggests checking serum potassium and creatinine within 1-2 weeks after any dose adjustment, then at 3 months, and subsequently every 6 months, with more frequent monitoring warranted if the patient has diabetes, heart failure, or concurrent use of other medications affecting potassium homeostasis 1, 3
The European Heart Journal recommends monitoring for hypokalemia more aggressively with loop diuretics, checking potassium within 3-7 days after initiation 1

The American College of Cardiology and the European Heart Journal recommend switching from HCTZ to a loop diuretic (furosemide 20-40 mg daily, bumetanide 0.5-1 mg daily, or torsemide 5-10 mg daily) for better volume control and blood pressure management at this level of renal function 1, 2
The European Heart Journal suggests considering discontinuing HCTZ rather than switching to a loop diuretic if blood pressure is well-controlled on losartan alone 2

The European Heart Journal recommends losartan + amlodipine (or another dihydropyridine CCB) as the preferred combination, as this pairing has demonstrated superior CVD event reduction compared to diuretic-based combinations 2
The American College of Cardiology suggests replacing HCTZ with loop diuretic (furosemide 20-40 mg daily, torsemide 5-10 mg daily) if diuretic is required for volume control, and monitoring potassium within 3-7 days 1

The European Heart Journal recommends targeting systolic BP 120-129 mmHg if well-tolerated, as this range provides optimal CVD risk reduction, and avoiding excessive diastolic BP lowering (<60 mmHg) in patients with CAD, diabetes, or age >60 years 2, 5
The American College of Cardiology and the European Heart Journal suggest checking potassium and creatinine within 1-2 weeks of any medication change, and avoiding combining losartan with potassium-sparing diuretics unless potassium is consistently <4.0 mEq/L 1, 2, 4

The American College of Cardiology, the European Heart Journal, and Circulation recommend avoiding NSAIDs and COX-2 inhibitors, dual RAS blockade (ACE inhibitor + ARB), and potassium supplements without close monitoring, as they can cause acute renal failure, sodium retention, and severe hyperkalemia when combined with losartan at eGFR 44 1, 2, 4, 5